Review



mean sd 347 8 b  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc mean sd 347 8 b
    Baseline Demographics and Disease Characteristics (Full Analysis Set)
    Mean Sd 347 8 B, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 31 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mean+sd+347+8+b/Phospho-Akt1+(Ser129)+Rabbit+mAb/pmc06136040-267-120-117
    Average 93 stars, based on 31 article reviews
    mean sd 347 8 b - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study"

    Article Title: Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study

    Journal: JAMA Ophthalmology

    doi: 10.1001/jamaophthalmol.2018.1804


    Figure Legend Snippet: Baseline Demographics and Disease Characteristics (Full Analysis Set)

    Techniques Used:

    Related Articles

    Injection:

    Article Title: Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study
    Article Snippet: .. The mean (SD) age at enrollment was 70.6 (8.4) years, and 222 participants (69.8%) were men. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Characteristic IAI Plus Sham PDT (n = 157) IAI Plus Active PDT (n = 161) Sex, No. (%) Male 110 (70.1) 112 (69.6) Female 47 (29.9) 49 (30.4) Race, No. (%) Asian 145 (92.4) 151 (93.8) Non-Asian 12 (7.6) 10 (6.2) Ethnicity, country, No. (%) Japanese 75 (47.8) 77 (47.8) Non-Japanese 82 (52.2) 84 (52.2) Age, mean (SD), y 70.8 (8.4) 70.4 (8.0) Disease duration, median, mo 0.49 a 0.39 Baseline BCVA score, mean (SD) 57.7 (11.3) 59.0 (11.5) Total NEI VFQ-25 score at baseline, mean (SD) 79.0 (11.5) 75.4 (14.6) Mean CST at baseline, mean (SD) 347.8 b (118.9) 346.1 c (117.5) Type of CNV lesions at screening, No. (%) CNV < 50% of lesion 22 (14.0) 19 (11.8) CNV > 50% of lesion Predominantly classic 23 (14.6) 13 (8.1) Minimally classic/occult 112 (71.3) 129 (80.1) Total lesion size at baseline, mean (SD), mm 2 8.13 (7.89) 7.91 (6.67) CNV size at baseline, mean (SD), mm 2 6.06 (6.28) 5.86 (5.06) d Presence of polypoidal lesions, detected with ICGA, No. (%) 139 (88.5) 143 (88.8) Presence of branch vessel network, No. (%) 122 (77.7) 138 (85.7) Presence of serous/hemorrhagic PED, No. (%) 78 (49.7) 70 (43.8) Smoking history, No. (%) Never 64 (40.8) 73 (45.3) Former 67 (42.7) 65 (40.4) Current 26 (16.6) 23 (14.3) Qualified for rescue therapy at week 12, No. (%) Rescue therapy 8 (5.1) 11 (6.8) Nonrescue therapy 149 (94.9) 150 (93.2) Open in a separate window Abbreviations: BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; CRT, central retinal thickness; CST, central subfield thickness; IAI, intravitreal aflibercept injection; ICGA, indocyanine green angiography; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; PDT, photodynamic therapy; PED, pigment epithelial detachment. a n = 156. b n = 152. c n = 158. d n = 160. caption a8 Baseline Demographics and Disease Characteristics (Full Analysis Set) ..

    Article Title: Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study
    Article Snippet: .. The mean (SD) age at enrollment was 70.6 (8.4) years, and 222 participants (69.8%) were men. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Characteristic IAI Plus Sham PDT (n = 157) IAI Plus Active PDT (n = 161) Sex, No. (%) Male 110 (70.1) 112 (69.6) Female 47 (29.9) 49 (30.4) Race, No. (%) Asian 145 (92.4) 151 (93.8) Non-Asian 12 (7.6) 10 (6.2) Ethnicity, country, No. (%) Japanese 75 (47.8) 77 (47.8) Non-Japanese 82 (52.2) 84 (52.2) Age, mean (SD), y 70.8 (8.4) 70.4 (8.0) Disease duration, median, mo 0.49 a 0.39 Baseline BCVA score, mean (SD) 57.7 (11.3) 59.0 (11.5) Total NEI VFQ-25 score at baseline, mean (SD) 79.0 (11.5) 75.4 (14.6) Mean CST at baseline, mean (SD) 347.8 b (118.9) 346.1 c (117.5) Type of CNV lesions at screening, No. (%) CNV < 50% of lesion 22 (14.0) 19 (11.8) CNV > 50% of lesion Predominantly classic 23 (14.6) 13 (8.1) Minimally classic/occult 112 (71.3) 129 (80.1) Total lesion size at baseline, mean (SD), mm 2 8.13 (7.89) 7.91 (6.67) CNV size at baseline, mean (SD), mm 2 6.06 (6.28) 5.86 (5.06) d Presence of polypoidal lesions, detected with ICGA, No. (%) 139 (88.5) 143 (88.8) Presence of branch vessel network, No. (%) 122 (77.7) 138 (85.7) Presence of serous/hemorrhagic PED, No. (%) 78 (49.7) 70 (43.8) Smoking history, No. (%) Never 64 (40.8) 73 (45.3) Former 67 (42.7) 65 (40.4) Current 26 (16.6) 23 (14.3) Qualified for rescue therapy at week 12, No. (%) Rescue therapy 8 (5.1) 11 (6.8) Nonrescue therapy 149 (94.9) 150 (93.2) Open in a separate window Abbreviations: BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; CRT, central retinal thickness; CST, central subfield thickness; IAI, intravitreal aflibercept injection; ICGA, indocyanine green angiography; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; PDT, photodynamic therapy; PED, pigment epithelial detachment. a n = 156. b n = 152. c n = 158. d n = 160. caption a8 Baseline Demographics and Disease Characteristics (Full Analysis Set) Treatment Experience Over 52 weeks, the mean number of IAIs for IAI monotherapy and IAI plus active PDT groups was 8.1 and 8.0, respectively; the mean number of PDT administrations (including sham) was 0.2 and 0.2, respectively. ..



    Similar Products

    mean sd 347 8 b  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc mean sd 347 8 b
    Baseline Demographics and Disease Characteristics (Full Analysis Set)
    Mean Sd 347 8 B, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mean+sd+347+8+b/Phospho-Akt1+(Ser129)+Rabbit+mAb/pmc06136040-267-120-117
    Average 93 stars, based on 1 article reviews
    mean sd 347 8 b - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Journal: JAMA Ophthalmology

    Article Title: Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study

    doi: 10.1001/jamaophthalmol.2018.1804

    Figure Lengend Snippet: Baseline Demographics and Disease Characteristics (Full Analysis Set)

    Article Snippet: The mean (SD) age at enrollment was 70.6 (8.4) years, and 222 participants (69.8%) were men. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Characteristic IAI Plus Sham PDT (n = 157) IAI Plus Active PDT (n = 161) Sex, No. (%) Male 110 (70.1) 112 (69.6) Female 47 (29.9) 49 (30.4) Race, No. (%) Asian 145 (92.4) 151 (93.8) Non-Asian 12 (7.6) 10 (6.2) Ethnicity, country, No. (%) Japanese 75 (47.8) 77 (47.8) Non-Japanese 82 (52.2) 84 (52.2) Age, mean (SD), y 70.8 (8.4) 70.4 (8.0) Disease duration, median, mo 0.49 a 0.39 Baseline BCVA score, mean (SD) 57.7 (11.3) 59.0 (11.5) Total NEI VFQ-25 score at baseline, mean (SD) 79.0 (11.5) 75.4 (14.6) Mean CST at baseline, mean (SD) 347.8 b (118.9) 346.1 c (117.5) Type of CNV lesions at screening, No. (%) CNV < 50% of lesion 22 (14.0) 19 (11.8) CNV > 50% of lesion Predominantly classic 23 (14.6) 13 (8.1) Minimally classic/occult 112 (71.3) 129 (80.1) Total lesion size at baseline, mean (SD), mm 2 8.13 (7.89) 7.91 (6.67) CNV size at baseline, mean (SD), mm 2 6.06 (6.28) 5.86 (5.06) d Presence of polypoidal lesions, detected with ICGA, No. (%) 139 (88.5) 143 (88.8) Presence of branch vessel network, No. (%) 122 (77.7) 138 (85.7) Presence of serous/hemorrhagic PED, No. (%) 78 (49.7) 70 (43.8) Smoking history, No. (%) Never 64 (40.8) 73 (45.3) Former 67 (42.7) 65 (40.4) Current 26 (16.6) 23 (14.3) Qualified for rescue therapy at week 12, No. (%) Rescue therapy 8 (5.1) 11 (6.8) Nonrescue therapy 149 (94.9) 150 (93.2) Open in a separate window Abbreviations: BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; CRT, central retinal thickness; CST, central subfield thickness; IAI, intravitreal aflibercept injection; ICGA, indocyanine green angiography; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; PDT, photodynamic therapy; PED, pigment epithelial detachment. a n = 156. b n = 152. c n = 158. d n = 160. caption a8 Baseline Demographics and Disease Characteristics (Full Analysis Set)

    Techniques: